Zhang Jian, Ma Linlin, Xie Zelin, Guo Yuwen, Sun Wen, Zhang Lei, Lin Jun, Xiao Jing, Zhu Yichen, Tian Ye
Department of Urology, Beijing Friendship Hospital Affiliated to Capital Medical University, No. 95 Yongan Road, Xicheng District, Beijing, 100050, China.
Med Oncol. 2014 Jul;31(7):32. doi: 10.1007/s12032-014-0032-6. Epub 2014 Jun 8.
This study investigated the incidence and types of post-transplant malignancy in Chinese renal transplant recipients and the risk factors associated with malignancy. Data from 3,462 patients who underwent renal transplantation at Beijing Friendship Hospital were combined with data from 26 previous reports describing malignancy rates in 27,170 Chinese renal transplant recipients. Between 1974 and 2014, 179/3,462 (5.17 %) patients who underwent renal transplantation at our center developed malignancy. The most common site of malignancy was the urinary system, and the most common type was urothelial transitional cell carcinoma. Combined data from our center and previous reports showed malignancy in 671 (2.19 %) Chinese renal transplant recipients. The ten most common malignancies were urothelial transitional cell carcinoma (n = 283), hepatocellular carcinoma (n = 68), gastrointestinal cancer (n = 63), renal cell carcinoma (n = 42), lymphoma (n = 42), lung cancer (n = 28), breast cancer (n = 19), skin cancer (n = 18), Kaposi's sarcoma (n = 12), and cervical cancer (n = 10). The incidence of post-transplant malignancy in renal transplant recipients was lower in China than the reported rates in other countries, and the most common sites of malignancy were the urinary and digestive system. The relative frequency of malignancy sites differed between northern and southern China. Renal transplant recipients on long-term immunosuppressive therapy should receive careful follow-up, including annual or biannual screening for malignancy in high-risk individuals.
本研究调查了中国肾移植受者移植后恶性肿瘤的发病率、类型以及与恶性肿瘤相关的危险因素。将北京友谊医院3462例接受肾移植患者的数据与之前26篇描述27170例中国肾移植受者恶性肿瘤发生率的报告数据相结合。1974年至2014年期间,在我们中心接受肾移植的患者中有179/3462例(5.17%)发生了恶性肿瘤。恶性肿瘤最常见的部位是泌尿系统,最常见的类型是尿路上皮移行细胞癌。我们中心和既往报告的综合数据显示,671例(2.19%)中国肾移植受者发生了恶性肿瘤。十种最常见的恶性肿瘤为尿路上皮移行细胞癌(n = 283)、肝细胞癌(n = 68)、胃肠道癌(n = 63)、肾细胞癌(n = 42)、淋巴瘤(n = 42)、肺癌(n = 28)、乳腺癌(n = 19)、皮肤癌(n = 18)、卡波西肉瘤(n = 12)和宫颈癌(n = 10)。中国肾移植受者移植后恶性肿瘤的发病率低于其他国家报告的发病率,恶性肿瘤最常见的部位是泌尿系统和消化系统。中国北方和南方恶性肿瘤的发病部位相对频率有所不同。长期接受免疫抑制治疗的肾移植受者应接受仔细随访,包括对高危个体每年或每半年进行一次恶性肿瘤筛查。